Will High Price Hurt Gilead Sciences’ New Hep-C Drug?

Last week, Gilead Sciences (GILD) finally got the go-ahead on Hepatitis-C treatment Horvani, which combines Solvaldi with Ledipsavir, and is supposed to cure from 94% to 99% of patients. And as with Sovaldi, critics are finding reasons to downplay the news, as issues around use and cost are making headlines. RBC Capital Markets’ Michael Yee [...]